Find us at Booth #623 and Restasis.com
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners. RMD106894 04/17
RESTASIS MultiDose
is available
INDICATIONS AND USAGE: RESTASIS
®
and RESTASIS MultiDose
TM
ophthalmic emulsion are indicated to increase tear production in patients whose tear production
is presumed to be suppressed due to ocular infl ammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently
taking topical anti-infl ammatory drugs or using punctal plugs.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: RESTASIS
®
and RESTASIS MultiDose
TM
are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients
in the formulation.
WARNINGS AND PRECAUTIONS
POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury
and contamination.
USE WITH CONTACT LENSES: RESTASIS
®
and RESTASIS MultiDose
TM
should not be administered while wearing contact lenses. If contact lenses are worn,
they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS
®
and RESTASIS
MultiDose
TM
ophthalmic emulsion.
ADVERSE REACTIONS: In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning
(upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation,
pruritus, stinging, and visual disturbance (most often blurring).
PLEASE SEE NEXT PAGE FOR A BRIEF SUMMARY OF THE FULL PRODUCT INFORMATION
REFERENCE: 1. RESTASIS
®
Prescribing Information, June 2013.
The same RESTASIS
®
(cyclosporine ophthalmic emulsion)
0.05% formulation is available in a preservative-free
multidose bottle or single-use vials
RESTASIS MultiDose
™
twice a day, ever y day, helps patients experience
increased tear production. Increased tear production was seen at 6 months.
1
For patients with decreased tear production
presumed to be due to ocular infl ammation
associated with chronic dry eye
TM
